Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab versus mycophenolate mofetil in childhood-onset idiopathic nephrotic syndrome
2022-000369-42Phase 3Active
- Sponsor
- Roche
- Start
- Nov 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Idiopathic nephrotic syndrome (INS) comparing Obinutuzumab with Mycophenolate mofetil (2 arms). Primary endpoint: Proportion of participants with sustained complete remission at 1 year. Started Nov 2022; status: active.
02
Drugs
obinutuzumabmycophenolate mofetil
03
Conditions
Idiopathic nephrotic syndrome (INS)
Beyond the preview
Go deeper on 2022-000369-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000369-42.